Pair Name | Oxidized tea polyphenol, Nimotuzumab | |||
Partner Name | Oxidized tea polyphenol | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
Up-regulation | Expression | BAX | hsa581 | |
Down-regulation | Expression | BCL2 | hsa596 | |
Down-regulation | Expression | EGFR | hsa1956 | |
Down-regulation | Phosphorylation | GSK3B | hsa2932 | |
Down-regulation | Phosphorylation | MAPK1 | hsa5594 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
Down-regulation | Phosphorylation | STAT3 | hsa6774 | |
In Vitro Model | NCI-H1781 | Minimally invasive lung adenocarcinoma | Homo sapiens (Human) | CVCL_1494 |
In Vivo Model | NCI-H1781 cells (5 × 106 cells per mice) were subcutaneously injected into the flank of each nu/nu mice. 3 days later, the mice were treated by intraperitoneal injection OTP-3 and nimotuzumab (three times per week) for the indicated period. | |||
Result | OTP-3 can also serve as an effective therapeutic agent in NSCLC where it can augment the effects of nimotuzumab, a valuable property for combination agents. |